SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
-7.14%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.28B
AUM Growth
+$1.28B
(-3.5%)
Cap. Flow
+$95.6M
Cap. Flow
% of AUM
7.5%
Top 10 Holdings %
Top 10 Hldgs %
50.86%
Holding
98
New
17
Increased
22
Reduced
20
Closed
23
Top Buys
| 1 |
NovoCure
NVCR
|
$49.6M |
| 2 |
STAAR Surgical
STAA
|
$45.2M |
| 3 |
BBNX
Beta Bionics, Inc. Common Stock
BBNX
|
$41.6M |
| 4 |
Praxis Precision Medicines
PRAX
|
$33.9M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$18.7M |
Top Sells
| 1 |
Axogen
AXGN
|
$27.9M |
| 2 |
AstraZeneca
AZN
|
$26.8M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$25.2M |
| 4 |
QuidelOrtho
QDEL
|
$24.4M |
| 5 |
Adaptive Biotechnologies
ADPT
|
$22.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
TG Therapeutics
TGTX
$4.65B
| $112M | 8.08% | 2,846,703 +165,461 | +6% | +$6.52M |
|
|
2
NovoCure
NVCR
$1.38B
| $98.4M | 7.08% | 5,521,414 +2,781,710 | +102% | +$49.6M |
|
3
Krystal Biotech
KRYS
$4.27B
| $79.6M | 5.73% | 441,758 +83,379 | +23% | +$15M |
|
4
BioMarin Pharmaceuticals
BMRN
$11.2B
| $76.3M | 5.49% | 1,079,304 +77,904 | +8% | +$5.51M |
|
5
Organogenesis Holdings
ORGO
$653M
| $53.9M | 3.88% | 12,478,351 -6,525 | -0.1% | -$28.2K |
|
6
Grifois
GRFS
$6.78B
| $50.4M | 3.63% | 7,089,822 +484,397 | +7% | +$3.44M |
|
7
United Therapeutics
UTHR
$13.8B
| $47.9M | 3.45% | 155,394 +46,000 | +42% | +$14.2M |
|
|
8
STAAR Surgical
STAA
$1.36B
| $45.2M | 3.25% | +2,562,893 | New | +$45.2M |
|
|
9
Praxis Precision Medicines
PRAX
$958M
| $43.2M | 3.11% | 1,139,740 +896,200 | +368% | +$33.9M |
|
|
BBNX
10
Beta Bionics, Inc. Common Stock
BBNX
$819M
| $41.6M | 2.99% | +3,395,341 | New | +$41.6M |
|
11
Neuropace
NPCE
$303M
| $32.1M | 2.31% | 2,608,168 +175,000 | +7% | +$2.15M |
|
12
Nurix Therapeutics
NRIX
$714M
| $28.8M | 2.07% | 2,422,833 +320,000 | +15% | +$3.8M |
|
|
13
Axogen
AXGN
$743M
| $26.8M | 1.93% | 1,446,117 -1,509,826 | -51% | -$27.9M |
|
14
Celcuity
CELC
$2.17B
| $26M | 1.87% | 2,574,122 +9,035 | +0.4% | +$91.3K |
|
15
Iovance Biotherapeutics
IOVA
$807M
| $25.9M | 1.87% | 7,785,000 +1,225,000 | +19% | +$4.08M |
|
16
Surmodics
SRDX
$487M
| $24.1M | 1.73% | 789,060 +395,000 | +100% | +$12.1M |
|
17
Integra LifeSciences
IART
$1.18B
| $23.6M | 1.7% | 1,072,204 -203,796 | -16% | -$4.48M |
|
18
Terns Pharmaceuticals
TERN
$609M
| $22.5M | 1.62% | 8,167,100 +24,600 | +0.3% | +$67.9K |
|
|
19
Madrigal Pharmaceuticals
MDGL
$9.76B
| $22.4M | 1.61% | 67,500 +56,600 | +519% | +$18.7M |
|
20
Insmed
INSM
$28.8B
| $20.9M | 1.51% | 274,272 -46,000 | -14% | -$3.51M |
|
21
Rigel Pharmaceuticals
RIGL
$697M
| $20.3M | 1.46% | 1,130,679 | – | – |
|
22
Hologic
HOLX
$14.9B
| $18.7M | 1.34% | +302,000 | New | +$18.7M |
|
23
argenx
ARGX
$43.6B
| $17.1M | 1.23% | +28,940 | New | +$17.1M |
|
24
Merus
MRUS
$4.98B
| $16.2M | 1.17% | 385,821 +73,500 | +24% | +$3.09M |
|
25
Nuvalent
NUVL
$5.52B
| $15.2M | 1.09% | 214,357 +110,000 | +105% | +$7.8M |
|